244 related articles for article (PubMed ID: 22791660)
1. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy.
Pramanik D; Campbell NR; Das S; Gupta S; Chenna V; Bisht S; Sysa-Shah P; Bedja D; Karikari C; Steenbergen C; Gabrielson KL; Maitra A; Maitra A
Oncotarget; 2012 Jun; 3(6):640-50. PubMed ID: 22791660
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
3. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
4. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
5. Intracellular self-disassemble polysaccharide nanoassembly for multi-factors tumor drug resistance modulation of doxorubicin.
Xiong H; Ni J; Jiang Z; Tian F; Zhou J; Yao J
Biomater Sci; 2018 Aug; 6(9):2527-2540. PubMed ID: 30105340
[TBL] [Abstract][Full Text] [Related]
6. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
[TBL] [Abstract][Full Text] [Related]
7. Lipid/Hyaluronic Acid-Coated Doxorubicin-Fe
Liang J; Yang X; Liu D; Cong M; Song Y; Bai S
AAPS PharmSciTech; 2020 Aug; 21(6):235. PubMed ID: 32803528
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.
Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ
Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro.
Kievit FM; Wang FY; Fang C; Mok H; Wang K; Silber JR; Ellenbogen RG; Zhang M
J Control Release; 2011 May; 152(1):76-83. PubMed ID: 21277920
[TBL] [Abstract][Full Text] [Related]
10. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.
Wang L; Wang W; Rui Z; Zhou D
Drug Deliv; 2016 Nov; 23(9):3200-3208. PubMed ID: 26987435
[TBL] [Abstract][Full Text] [Related]
11. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.
Apte A; Koren E; Koshkaryev A; Torchilin VP
Cancer Biol Ther; 2014 Jan; 15(1):69-80. PubMed ID: 24145298
[TBL] [Abstract][Full Text] [Related]
13. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.
Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H
Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129
[TBL] [Abstract][Full Text] [Related]
14. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
[TBL] [Abstract][Full Text] [Related]
15. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664
[TBL] [Abstract][Full Text] [Related]
16. Selection and optimization of nano-formulation of P-glycoprotein inhibitor for reversal of doxorubicin resistance in COLO205 cells.
Dash TK; Konkimalla VSB
J Pharm Pharmacol; 2017 Jul; 69(7):834-843. PubMed ID: 28397291
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization.
Mallappa S; Neeli PK; Karnewar S; Kotamraju S
Mol Carcinog; 2019 Jul; 58(7):1118-1133. PubMed ID: 30834613
[TBL] [Abstract][Full Text] [Related]
18. Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model.
Zhou ZY; Wan LL; Yang QJ; Han YL; Li D; Lu J; Guo C
Toxicol Lett; 2016 Sep; 259():124-132. PubMed ID: 27491883
[TBL] [Abstract][Full Text] [Related]
19. Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model.
Shuhendler AJ; Prasad P; Zhang RX; Amini MA; Sun M; Liu PP; Bristow RG; Rauth AM; Wu XY
Mol Pharm; 2014 Aug; 11(8):2659-74. PubMed ID: 24830351
[TBL] [Abstract][Full Text] [Related]
20. A nanoparticulate pre-chemosensitizer for efficacious chemotherapy of multidrug resistant breast cancer.
Guo S; Lv L; Shen Y; Hu Z; He Q; Chen X
Sci Rep; 2016 Feb; 6():21459. PubMed ID: 26875787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
